Towards a Unifying Hypothesis of Alzheimers Disease: Cholinergic System Linked to Plaques, Tangles and Neuroinflammation
The DOI matches its Crossref record.
Abstract
The central role of cholinergic system in Alzheimer's disease (AD) pathway is becoming increasingly significant as reports linking the various components of cholinergic neurotransmission with the other pathological hallmarks emerge. This review, while addressing the molecular mechanisms associated with the pathological hallmarks of the disease and their close interactions, also makes an attempt to address the critical question that evades an answer: Given the significant role played by cholinergic system in AD pathway, why do the cholinergic-mechanism-based drugs are not successful in reversing or arresting the disease progress? Further, as molecules of diverse structural features were shown to inhibit amyloid aggregation, an understanding of the generic pathway of amyloid aggregation slowly emerges. For the first time, a coherent view of amyloid aggregation is presented in this review. The possible role of neuroinflammatory response in the events leading to the degeneration of cholinergic neurons is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Impact of Anticholinergics on the Aging Brain: A Review and Practical Application
Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008) · Aging Health · doi:10.2217/1745509x.4.3.311 · Cited by 862
Huperzine A from Huperzia species—An ethnopharmacolgical review
Ma, X., Tan, C., Zhu, D., Gang, D. R., & Xiao, P. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.05.030 · Cited by 291
Amyloid beta peptides and glutamatergic synaptic dysregulation
Parameshwaran, K., Dhanasekaran, M., & Suppiramaniam, V. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.10.008 · Cited by 235
Mandel, S., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.06.001 · Cited by 164
Han, X. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04708.x · Cited by 101
“…hypothesis), energy metabolism, and acetylcholine signaling defects, among others (Armstrong et al. 1996; Albers and Beal 2000; Cummings and Cole 2002; Mattson 2003; McGeer and McGeer 2003; Selkoe 2004; Hauptmann et al. 2006; Ony- ango and Khan 2006; Sivaprakasam 2006; Tabet 2006; Wyss-Coray 2006).”
BackgroundMorgan, A. R., Turic, D., Jehu, L., Hamilton, G., Hollingworth, P., Moskvina, V., Jones, L., Lovestone, S., Brayne, C., Rubinsztein, D. C., et al. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30509 · Cited by 42
Chen, G., Chen, P., Tan, H., Ma, D., Dou, F., Feng, J., & Yan, Z. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.023 · Cited by 36
Liu, H.-P., Lin, W.-Y., Liu, S.-H., Wang, W.-F., Tsai, C.-H., Wu, B.-T., Wang, C.-K., & Tsai, F.-J. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000254757 · Cited by 29
“Additionally, excitatory neurotransmission involved in cholinergic and glutamatergic systems is responsible for Aβ alteration in the progression of AD [”
Metadata
- Authors
- Sivaprakasam, K.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-08-01
- Volume
- 13
- Issue
- 18
- Pages
- 2179-2188
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2061114904
- Cited by
- 67
- References
- 0
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.